MiNK 215
Alternative Names: Allo-FAP-CAR-iNKT-MiNK Therapeutics; FAP-CAR-iNKT; MiNK-215; Stromal CAR iNKT - Agenus; Stromal Target-CAR-iNKT-MiNK Therapeutics; Stromal-CAR-iNKTLatest Information Update: 20 May 2024
At a glance
- Originator Agenus
- Developer MiNK Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural Killer T-cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 May 2024 MiNK Therapeutics plans a first-in-human clinical trial for Solid tumours (Parenteral) in early 2025
- 08 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by MiNK Therapeutics
- 20 Sep 2023 Preclinical data in Non-small cell lung cancer presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)